| # | Drug | Count |
|---|---|---|
| 0 | CONJUGATED ESTROGENS | 164 |
| 1 | ESTROGENS, CONJUGATED | 164 |
| 2 | BEVACIZUMAB | 113 |
| 3 | CARBOPLATIN | 106 |
| 4 | CONJUGATED ESTROGENS AND MEDROXYPROGESTERONE ACETATE | 100 |
| 5 | PACLITAXEL | 81 |
| 6 | PACLITAXEL (AIBUMIN-BOUND) | 76 |
| 7 | MEDROXYPROGESTERONE ACETATE | 71 |
| 8 | NIRAPARIB | 70 |
| 9 | ADALIMUMAB | 50 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | ESTERIFIED ESTROGENS AND METHYLTESTOSTERONE | 4 | 0.0108 |
| 1 | ESTERIFIED ESTROGENS, METHYLTESTOSTERONE | 4 | 0.0108 |
| 2 | BELINOSTAT | 3 | 0.0084 |
| 3 | MIRVETUXIMAB SORAVTANSINE | 12 | 0.0066 |
| 4 | PENICILLAMINE | 6 | 0.0065 |
| 5 | ILOPROST | 6 | 0.0064 |
| 6 | CONJUGATED ESTROGENS AND MEDROXYPROGESTERONE ACETATE | 100 | 0.0043 |
| 7 | TRABECTEDIN | 9 | 0.0038 |
| 8 | NIRAPARIB | 70 | 0.0032 |
| 9 | CONJUGATED ESTROGENS | 164 | 0.0028 |
| # | Drug class | Count |
|---|---|---|
| 0 | Estrogen [EPC] | 182 |
| 1 | Vascular Endothelial Growth Factor Inhibitor [EPC] | 121 |
| 2 | Platinum-based Drug [EPC] | 113 |
| 3 | Microtubule Inhibitor [EPC] | 89 |
| 4 | Tumor Necrosis Factor Blocker [EPC] | 58 |
| 5 | Nonsteroidal Anti-inflammatory Drug [EPC] | 48 |
| 6 | Aromatase Inhibitor [EPC] | 46 |
| 7 | Corticosteroid [EPC] | 44 |
| 8 | Folate Analog Metabolic Inhibitor [EPC] | 39 |
| 9 | Poly(ADP-Ribose) Polymerase Inhibitor [EPC] | 37 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Prostacycline [EPC] | 6 | 0.0064 |
| 1 | Poly(ADP-Ribose) Polymerase Inhibitor [EPC] | 37 | 0.0017 |
| 2 | Estrogen [EPC] | 182 | 0.0010 |
| 3 | Guanylate Cyclase-C Agonist [EPC] | 2 | 0.0010 |
| 4 | Calcitonin [EPC] | 3 | 0.0010 |
| 5 | Histone Deacetylase Inhibitor [EPC] | 3 | 0.0008 |
| 6 | Vascular Endothelial Growth Factor Inhibitor [EPC] | 121 | 0.0007 |
| 7 | Provitamin D2 Compound [EPC] | 19 | 0.0006 |
| 8 | Microtubule Inhibitor [EPC] | 89 | 0.0005 |
| 9 | Platinum-based Drug [EPC] | 113 | 0.0004 |